(TECH) Bio-Techne - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09073M1045
Stock: Cytokines, Antibodies, Assays, Instruments, Reagents
Total Rating 53
Risk 90
Buy Signal 0.11
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.57% |
| Yield on Cost 5y | 0.34% |
| Yield CAGR 5y | -29.29% |
| Payout Consistency | 95.0% |
| Payout Ratio | 16.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 41.2% |
| Relative Tail Risk | -7.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.13 |
| Alpha | -28.60 |
| Character TTM | |
|---|---|
| Beta | 1.191 |
| Beta Downside | 1.046 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.32% |
| CAGR/Max DD | -0.08 |
Description: TECH Bio-Techne January 06, 2026
Bio-Techne Corp (NASDAQ: TECH) supplies life-science reagents, instruments, and services across research, diagnostics, and bioprocessing, organized into two divisions: Protein Sciences and Diagnostics & Spatial Biology. The Protein Sciences arm produces cytokines, growth factors, antibodies, and automated proteomic tools, while the Diagnostics segment offers assay controls, exosome-based tests, spatial-genomics kits, and hematology reagents.
Key metrics (FY 2023) show revenue of roughly $1.5 billion, up about 10 % YoY, with an operating margin near 13 % and R&D spending at ~12 % of sales-both above the industry average. The company’s growth is bolstered by the ~8 % CAGR expansion of the cell-and-gene-therapy reagent market and rising adoption of spatial-biology platforms, while recent acquisitions (e.g., Asuragen in 2022) have broadened its genomics footprint.
If you want a data-driven, quantitative deep-dive, the analytical tools on ValueRay may be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 81.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.68 > 1.0 |
| NWC/Revenue: 40.89% < 20% (prev 39.58%; Δ 1.31% < -1%) |
| CFO/TA 0.10 > 3% & CFO 249.3m > Net Income 81.1m |
| Net Debt (164.3m) to EBITDA (227.2m): 0.72 < 3 |
| Current Ratio: 4.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (157.0m) vs 12m ago -2.26% < -2% |
| Gross Margin: 65.22% > 18% (prev 0.66%; Δ 6456 % > 0.5%) |
| Asset Turnover: 46.81% > 50% (prev 44.79%; Δ 2.03% > 0%) |
| Interest Coverage Ratio: 13.29 > 6 (EBITDA TTM 227.2m / Interest Expense TTM 9.29m) |
Altman Z'' 5.29
| A: 0.20 (Total Current Assets 637.4m - Total Current Liabilities 140.4m) / Total Assets 2.52b |
| B: 0.44 (Retained Earnings 1.11b / Total Assets 2.52b) |
| C: 0.05 (EBIT TTM 123.5m / Avg Total Assets 2.60b) |
| D: 2.14 (Book Value of Equity 1.05b / Total Liabilities 488.6m) |
| Altman-Z'' Score: 5.29 = AAA |
Beneish M -3.22
| DSRI: 0.83 (Receivables 184.6m/217.9m, Revenue 1.22b/1.20b) |
| GMI: 1.01 (GM 65.22% / 65.62%) |
| AQI: 0.99 (AQ_t 0.63 / AQ_t-1 0.64) |
| SGI: 1.02 (Revenue 1.22b / 1.20b) |
| TATA: -0.07 (NI 81.1m - CFO 249.3m) / TA 2.52b) |
| Beneish M-Score: -3.22 (Cap -4..+1) = AA |
What is the price of TECH shares?
As of February 07, 2026, the stock is trading at USD 66.78 with a total of 1,547,126 shares traded.
Over the past week, the price has changed by +4.20%, over one month by +2.30%, over three months by +14.94% and over the past year by -10.47%.
Over the past week, the price has changed by +4.20%, over one month by +2.30%, over three months by +14.94% and over the past year by -10.47%.
Is TECH a buy, sell or hold?
Bio-Techne has received a consensus analysts rating of 4.13.
Therefore, it is recommended to buy TECH.
- StrongBuy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TECH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 74.3 | 11.2% |
| Analysts Target Price | 74.3 | 11.2% |
| ValueRay Target Price | 69.9 | 4.6% |
TECH Fundamental Data Overview February 07, 2026
P/E Trailing = 124.2642
P/E Forward = 34.4828
P/S = 8.4686
P/B = 5.3206
P/EG = 0.8316
Revenue TTM = 1.22b USD
EBIT TTM = 123.5m USD
EBITDA TTM = 227.2m USD
Long Term Debt = 346.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 28.2m USD (from shortTermDebt, last fiscal year)
Debt = 337.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 164.3m USD (from netDebt column, last quarter)
Enterprise Value = 10.47b USD (10.30b + Debt 337.2m - CCE 172.9m)
Interest Coverage Ratio = 13.29 (Ebit TTM 123.5m / Interest Expense TTM 9.29m)
EV/FCF = 46.94x (Enterprise Value 10.47b / FCF TTM 223.0m)
FCF Yield = 2.13% (FCF TTM 223.0m / Enterprise Value 10.47b)
FCF Margin = 18.35% (FCF TTM 223.0m / Revenue TTM 1.22b)
Net Margin = 6.67% (Net Income TTM 81.1m / Revenue TTM 1.22b)
Gross Margin = 65.22% ((Revenue TTM 1.22b - Cost of Revenue TTM 422.8m) / Revenue TTM)
Gross Margin QoQ = 64.65% (prev 65.65%)
Tobins Q-Ratio = 4.15 (Enterprise Value 10.47b / Total Assets 2.52b)
Interest Expense / Debt = 0.64% (Interest Expense 2.17m / Debt 337.2m)
Taxrate = 25.16% (12.8m / 50.8m)
NOPAT = 92.4m (EBIT 123.5m * (1 - 25.16%))
Current Ratio = 4.54 (Total Current Assets 637.4m / Total Current Liabilities 140.4m)
Debt / Equity = 0.17 (Debt 337.2m / totalStockholderEquity, last quarter 2.03b)
Debt / EBITDA = 0.72 (Net Debt 164.3m / EBITDA 227.2m)
Debt / FCF = 0.74 (Net Debt 164.3m / FCF TTM 223.0m)
Total Stockholder Equity = 1.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.12% (Net Income 81.1m / Total Assets 2.52b)
RoE = 4.09% (Net Income TTM 81.1m / Total Stockholder Equity 1.98b)
RoCE = 5.30% (EBIT 123.5m / Capital Employed (Equity 1.98b + L.T.Debt 346.0m))
RoIC = 4.03% (NOPAT 92.4m / Invested Capital 2.29b)
WACC = 10.00% (E(10.30b)/V(10.64b) * Re(10.31%) + D(337.2m)/V(10.64b) * Rd(0.64%) * (1-Tc(0.25)))
Discount Rate = 10.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.96%
[DCF Debug] Terminal Value 69.64% ; FCFF base≈235.5m ; Y1≈217.7m ; Y5≈196.8m
Fair Price DCF = 15.21 (EV 2.54b - Net Debt 164.3m = Equity 2.38b / Shares 156.5m; r=10.00% [WACC]; 5y FCF grow -9.56% → 2.90% )
EPS Correlation: -23.36 | EPS CAGR: -4.19% | SUE: 1.14 | # QB: 1
Revenue Correlation: 50.42 | Revenue CAGR: 0.50% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.54 | Chg30d=-0.028 | Revisions Net=-2 | Analysts=9
EPS current Year (2026-06-30): EPS=1.99 | Chg30d=+0.018 | Revisions Net=-4 | Growth EPS=+3.6% | Growth Revenue=+0.4%
EPS next Year (2027-06-30): EPS=2.17 | Chg30d=+0.003 | Revisions Net=-4 | Growth EPS=+9.1% | Growth Revenue=+6.5%
P/E Forward = 34.4828
P/S = 8.4686
P/B = 5.3206
P/EG = 0.8316
Revenue TTM = 1.22b USD
EBIT TTM = 123.5m USD
EBITDA TTM = 227.2m USD
Long Term Debt = 346.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 28.2m USD (from shortTermDebt, last fiscal year)
Debt = 337.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 164.3m USD (from netDebt column, last quarter)
Enterprise Value = 10.47b USD (10.30b + Debt 337.2m - CCE 172.9m)
Interest Coverage Ratio = 13.29 (Ebit TTM 123.5m / Interest Expense TTM 9.29m)
EV/FCF = 46.94x (Enterprise Value 10.47b / FCF TTM 223.0m)
FCF Yield = 2.13% (FCF TTM 223.0m / Enterprise Value 10.47b)
FCF Margin = 18.35% (FCF TTM 223.0m / Revenue TTM 1.22b)
Net Margin = 6.67% (Net Income TTM 81.1m / Revenue TTM 1.22b)
Gross Margin = 65.22% ((Revenue TTM 1.22b - Cost of Revenue TTM 422.8m) / Revenue TTM)
Gross Margin QoQ = 64.65% (prev 65.65%)
Tobins Q-Ratio = 4.15 (Enterprise Value 10.47b / Total Assets 2.52b)
Interest Expense / Debt = 0.64% (Interest Expense 2.17m / Debt 337.2m)
Taxrate = 25.16% (12.8m / 50.8m)
NOPAT = 92.4m (EBIT 123.5m * (1 - 25.16%))
Current Ratio = 4.54 (Total Current Assets 637.4m / Total Current Liabilities 140.4m)
Debt / Equity = 0.17 (Debt 337.2m / totalStockholderEquity, last quarter 2.03b)
Debt / EBITDA = 0.72 (Net Debt 164.3m / EBITDA 227.2m)
Debt / FCF = 0.74 (Net Debt 164.3m / FCF TTM 223.0m)
Total Stockholder Equity = 1.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.12% (Net Income 81.1m / Total Assets 2.52b)
RoE = 4.09% (Net Income TTM 81.1m / Total Stockholder Equity 1.98b)
RoCE = 5.30% (EBIT 123.5m / Capital Employed (Equity 1.98b + L.T.Debt 346.0m))
RoIC = 4.03% (NOPAT 92.4m / Invested Capital 2.29b)
WACC = 10.00% (E(10.30b)/V(10.64b) * Re(10.31%) + D(337.2m)/V(10.64b) * Rd(0.64%) * (1-Tc(0.25)))
Discount Rate = 10.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.96%
[DCF Debug] Terminal Value 69.64% ; FCFF base≈235.5m ; Y1≈217.7m ; Y5≈196.8m
Fair Price DCF = 15.21 (EV 2.54b - Net Debt 164.3m = Equity 2.38b / Shares 156.5m; r=10.00% [WACC]; 5y FCF grow -9.56% → 2.90% )
EPS Correlation: -23.36 | EPS CAGR: -4.19% | SUE: 1.14 | # QB: 1
Revenue Correlation: 50.42 | Revenue CAGR: 0.50% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.54 | Chg30d=-0.028 | Revisions Net=-2 | Analysts=9
EPS current Year (2026-06-30): EPS=1.99 | Chg30d=+0.018 | Revisions Net=-4 | Growth EPS=+3.6% | Growth Revenue=+0.4%
EPS next Year (2027-06-30): EPS=2.17 | Chg30d=+0.003 | Revisions Net=-4 | Growth EPS=+9.1% | Growth Revenue=+6.5%